Author： Brinker A.
Publisher： Adis International
ISSN： 1170-229X
Source： Drugs & Aging, Vol.21, Iss.7, 2004-01, pp. : 479-484
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Fewer GI complications with rofecoxib and celecoxib
Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. :
Access to resources
Recommend
Celecoxib and rofecoxib ADRs compared with meloxicam
Inpharma, Vol. 1, Iss. 1409, 2003-01 ,pp. :
Celecoxib and rofecoxib: risk of GI bleeding
Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. :
Factors associated with celecoxib, rofecoxib use in the US
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 479, 2005-01 ,pp. :
Cost effectiveness of celecoxib, rofecoxib in OA and RA
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 352, 2002-01 ,pp. :